4D Molecular Therapeutics (NASDAQ:FDMT) rose 11.32% on June 23, 2026, as gene therapy momentum fueled a small-cap rebound, with shares closing at $11.60.

Key Highlights

  • Rose 11.32%: 4D Molecular Therapeutics closed at $11.60 on June 23 after moving $1.18 per share.
  • Catalyst: During the session, gene therapy momentum fueled a small-cap rebound.
  • Company: 4D Molecular Therapeutics develops genetic medicines using targeted adeno-associated virus vectors across several therapeutic areas.
  • Session: The stock finished at $11.60, while the available company record showed no new material filing for the move.

4D Molecular Therapeutics (NASDAQ:FDMT) rose 11.32% on June 23, 2026, closing at $11.60 after a $1.18 per-share move. The session’s advance came as gene therapy momentum fueled a small-cap rebound, based on the available company disclosures and trading context.

No company-specific announcement was found for the session; the move appeared to reflect broader gene-therapy sector enthusiasm and short-covering in a thinly traded small-cap biotech. FDMT is developing novel gene therapy candidates across ophthalmology, pulmonology, and cardiology.

4D Molecular Therapeutics develops genetic medicines using targeted adeno-associated virus vectors across several therapeutic areas.

The stock has been volatile since pausing certain clinical activities, making it reactive to sector-level sentiment shifts. No regulatory or clinical milestone was filed during the session.

No earnings release, contract award, financing transaction or regulatory filing was identified as a new trigger for the June 23 move. That leaves the day’s $1.18 change linked to trading conditions, including liquidity, positioning and technical demand rather than a confirmed change in operations.

Thinly traded shares can record large percentage changes when a relatively small number of orders meets limited available supply. The closing price of $11.60 therefore records the market move, but it does not by itself establish a new fundamental development at 4D Molecular Therapeutics.

For the June 23 close, the defining facts were the 11.32% advance, the $11.60 closing price and the catalyst described above. Any further change in the investment record would require a new filing, financial update, regulatory communication or transaction announcement from the company.